Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Eur Urol. 2020 Aug 1;78(6):907–915. doi: 10.1016/j.eururo.2020.07.018

Fig. 3 –

Fig. 3 –

(A) Recurrence-free survival and (B) overall survival by FGFR3 mutation status in the TCGA bladder cancer subset who received adjuvant chemotherapy; (C) recurrence-free survival and (D) overall survival in the TCGA bladder cancer subset who did not receive perioperative chemotherapy. All analyses are log-rank tests and not adjusted for other variables. FGFR3 = fibroblast growth factor receptor 3; TCGA = The Cancer Genome Atlas.